Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells

被引:28
作者
Spetz, AL
Sörensen, AS
Walther-Jallow, L
Wahren, B
Andersson, J
Holmgren, L
Hinkula, J
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Ctr Infect Med, Dept Med, S-14186 Huddinge, Sweden
[2] Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden
[3] Swedish Inst Infect Dis, Stockholm, Sweden
[4] Karolinska Inst, Karolinska Hosp, Ctr Canc, S-10401 Stockholm, Sweden
[5] Malmo Univ, Dept Hlth & Soc, Malmo, Sweden
关键词
D O I
10.4049/jimmunol.169.10.5771
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ag-presenting dendritic cells present viral Ags to T cells after uptake of apoptotic bodies derived from virus-infected cells in vitro. However, it is unclear whether apoptotic virus-infected cells are capable of generating immunity in vivo. In this study, we show that inoculation of mice With apoptotic HIV-1/murine leukemia virus (MuLV)-infected cells induces HIV-1-specific immunity. Immunization with apoptotic HIV-1/MuLV-infected syngeneic splenocytes resulted in strong Nef-specific CD8(+) T cell proliferation and p24-induced CD4(+) and CD8(+) T cell proliferation as well as IFN-gamma production. In addition, systemic IgG and IgA as well as mucosa-associated IgA responses were generated. Moreover, mice vaccinated with apoptotic HIV-1/MuLV cells were protected against challenge with live HIV-1/MuLV-infected cells, whereas mice vaccinated with apoptotic noninfected or MuLV-infected splenocytes remained susceptible to HIV-1/MuLV. These data show that i.p. immunization with apoptotic HIV-1-infected cells induces high levels of HIV-1-specific systemic immunity, primes for mucosal immunity, and induces protection against challenge with live HIV-1-infected cells in mice. These findings may have implications for the development of therapeutic and prophylactic HIV-1 vaccines.
引用
收藏
页码:5771 / 5779
页数:9
相关论文
共 53 条
[21]   Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA [J].
Krieg, AM .
TRENDS IN MICROBIOLOGY, 1996, 4 (02) :73-77
[22]   Regulation of T cell immunity by dendritic cells [J].
Lanzavecchia, A ;
Sallusto, F .
CELL, 2001, 106 (03) :263-266
[23]   Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus [J].
Larsson, M ;
Fonteneau, JF ;
Lirvall, M ;
Haslett, P ;
Lifson, JD ;
Bhardwaj, N .
AIDS, 2002, 16 (10) :1319-1329
[24]   Proteosomes, emulsomes, and cholera toxin B improve nasal Immunogenicity of human immunodeficiency virus gp160 in mice: Induction of serum, intestinal, vaginal, and lung IgA and IgG [J].
Lowell, GH ;
Kaminski, RW ;
VanCott, TC ;
Slike, B ;
Kersey, K ;
Zawoznik, E ;
LoomisPrice, L ;
Smith, G ;
Redfield, RR ;
Amselem, S ;
Birx, DL .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (02) :292-301
[25]   Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA [J].
Lundholm, P ;
Asakura, Y ;
Hinkula, J ;
Lucht, E ;
Wahren, B .
VACCINE, 1999, 17 (15-16) :2036-2042
[26]   Comparison of in-house and commercial sample preparation and PCR amplification systems for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults [J].
Lyamuya, E ;
BredbergRaden, U ;
Albert, J ;
Grankvist, O ;
Msangi, V ;
Kagoma, C ;
Mhalu, F ;
Biberfeld, G .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) :278-280
[27]   HIV-1 sequence variation: Drift, shift, and attenuation [J].
Malim, MH ;
Emerman, M .
CELL, 2001, 104 (04) :469-472
[28]   Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies [J].
Mantis, NJ ;
Kozlowski, PA ;
Mielcarz, DW ;
Weissenhorn, W ;
Neutra, MR .
VACCINE, 2001, 19 (28-29) :3990-4001
[29]   An innate sense of danger [J].
Matzinger, P .
SEMINARS IN IMMUNOLOGY, 1998, 10 (05) :399-415
[30]   TOLERANCE, DANGER, AND THE EXTENDED FAMILY [J].
MATZINGER, P .
ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :991-1045